| Bioactivity | Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells[1]. |
| Invitro | Siplizumab (MEDI-507; 0.00001-10 nM) 结合 FcγR 并诱导信号转导[1]。Siplizumab (0.0001-10 μg/mL) 介导细胞耗竭并降低 T 细胞增殖[1]。 |
| Name | Siplizumab |
| CAS | 288392-69-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Binder C, et, al. Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro. Front Immunol. 2020 Nov 11;11:592553. |